Search results
Results From The WOW.Com Content Network
This is defined as a left ventricular ejection fraction (LVEF) of 40% or less. About half of heart failure patients have a reduced ejection fraction. [2] Other types of heart failure are heart failure with mildly reduced ejection fraction (LVEF between 40% and 50%) and heart failure with preserved ejection fraction (LVEF 50% or higher). [1] [3]
Heart failure with preserved ejection fraction (HFpEF) is a form of heart failure in which the ejection fraction – the percentage of the volume of blood ejected from the left ventricle with each heartbeat divided by the volume of blood when the left ventricle is maximally filled – is normal, defined as greater than 50%; [1] this may be measured by echocardiography or cardiac catheterization.
Modalities applied to measurement of ejection fraction is an emerging field of medical mathematics and subsequent computational applications. The first common measurement method is echocardiography, [7] [8] although cardiac magnetic resonance imaging (MRI), [8] [9] cardiac computed tomography, [8] [9] ventriculography and nuclear medicine (gated SPECT and radionuclide angiography) [8] [10 ...
In 2015, it affected about 40 million people worldwide. [8] Overall, heart failure affects about 2% of adults, [22] and more than 10% of those over the age of 70. [6] Rates are predicted to increase. [22] The risk of death in the first year after diagnosis is about 35%, while the risk of death in the second year is less than 10% in those still ...
With Left Ventricular Ejection Fraction (LVEF) ≤ 35% due to prior Myocardial Infarction (MI) who are at least 40 days post-MI and are in NYHA Functional Class II or III; With Left Ventricular (LV) dysfunction due to prior MI who are at least 40 days post-MI, have an LVEF ≤ 30%, and are in NYHA Functional Class I
Cardiac symptoms of heart failure include chest pain/pressure and palpitations.Common noncardiac signs and symptoms of heart failure include loss of appetite, nausea, weight loss, bloating, fatigue, weakness, low urine output, waking up at night to urinate, and cerebral symptoms of varying severity, ranging from anxiety to memory impairment and confusion.
On a stand-alone basis, Globus Medical reaffirms its full year 2025 revenue guidance of $2.66 billion to $2.69 billion, and fully diluted non-GAAP earnings per share range between $3.40 to $3.50.
The FDA approved the OPTIMIZER Smart System, which delivers cardiac contractility modulation therapy, as indicated to improve 6-minute hall walk distance, quality of life, and functional status of NYHA Class III heart failure patients who remain symptomatic despite guideline directed medical therapy, who are in normal sinus rhythm, are not indicated for cardiac resynchronization therapy, and ...